Interestingly, we observed that GBM-N019 synergized with palbociclib and significantly delayed tumor growth with concomitant suppression of p-mTOR, mTORC1, mTORC2, Akt, NF-κB, STAT3, and CDK6 when compared to individual therapies. Here, MTOR is linked to glioblastoma.